IMMUNOPARESIS AT DIAGNOSIS IS AN ADVERSE PROGNOSTIC FACTOR FOR PROGRESSION FREE-SURVIVAL AND OVERALL SURVIVAL IN MULTIPLE MYELOMA

EHA Library, Teresa Ribeiro, 293516

REAL-LIFE BORTEZOMIB MAINTENANCE PROVIDES SIMILAR OUTCOMES TO THOSE REPORTED WITH ALTERNATIVE MAINTENANCE STRATEGIES: A MULTISITE RETROSPECTIVE STUDY.

EHA Library, Efrat Luttwak, 293517

HEALTH-RELATED QUALITY OF LIFE IN HEAVILY PRE-TREATED AND RENALLY IMPAIRED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE: ICARIA-MM STUDY

EHA Library, Meletios Dimopoulos, 293518

HORIZON (OP-106): AN EXPLORATORY ANALYSIS OF TIME TO NEXT TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED MELFLUFEN PLUS DEXAMETHASONE

EHA Library, María-Victoria Mateos, 293519

LIMITED EFFICACY OF DARATUMUMAB IN MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE

EHA Library, Tomas Jelinek, 293520

DREAMM-6: SAFETY AND TOLERABILITY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH BORTEZOMIB/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Rakesh Popat, 293521

PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH TRIPLE CLASS REFRACTORY MULTIPLE MYELOMA

EHA Library, Maneesha Mehra, 293522

A SYSTEMATIC LITERATURE REVIEW TO ASSESS EFFICACY OF TREATMENTS IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS

EHA Library, Faith Davies, 293523

FRONTLINE (FL) TREATMENT PATTERNS AND USE OF MAINTENANCE THERAPY (MT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS NOT RECEIVING FL STEM CELL TRANSPLANT (NSCT)

EHA Library, Dasha Cherepanov, 293524

THE PERCENTAGE OF ABNORMAL PLASMA CELL AMONG TOTAL BM PLASMA CELLS PREDICTED THE DISEASE PROGRESSION AFTER MRD REAPPEARANCE IN PATIENTS WITH TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Jingli Gu, 293525

IXAZOMIB REAL-LIFE-SETTING USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: REMIX, A PROSPECTIVE, NON-INTERVENTIONAL STUDY

EHA Library, Lauriane Filliatre-Clément, 293526

DREAMM-2: SINGLE-AGENT BELANTAMAB MAFODOTIN (GSK2857916) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) AND HIGH-RISK (HR) CYTOGENETICS

EHA Library, Suzanne Trudel, 293527

CORTICOSTERIOD TAPERING IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA RECEIVING SUBCUTANEOUS DARATUMUMAB (DARA SC): PART 3 OF THE OPEN-LABEL, MULTICENTER, PHASE 1B PAVO STUDY

EHA Library, Hareth Nahi, 293528

EVOLVING OUTCOMES IN MM REAL-WORLD PRACTICE: 20-YEARS SINGLE CENTER EXPERIENCE

EHA Library, Claudia Bellofiore, 293529

PROFILE CHARACTERISTICS OF LONG-TERM SURVIVORS IN MULTIPLE MYELOMA

EHA Library, Florence Sabirou, 293530

24-H URINE: IS IT REALLY NECESSARY FOR MULTIPLE MYELOMA FOLLOW-UP?

EHA Library, Joao Pedro Barreto, 293531

HEMATOLOGIC MALIGNACIES AND GAMMOPATHIES IN GAUCHER DISEASE TYPE 1

EHA Library, Maria Domenica Cappellini, 293533

MULTIPLE MYELOMA FRAILTY POPULATION IN SPAIN: PRELIMINARY ANALYSIS OF THE INSIGHT MM REGISTRY

EHA Library, Noemi Puig, 293534

THE ORAL MICROBIOME IN PATIENTS WITH RELAPSED/REFRACTORY MYELOMA TREATED WITH IXAZOMIB-THALIDOMIDE-DEXAMETHASONE (AGMT_MM-1 PHASE II TRIAL)

EHA Library, Heinz Ludwig, 293535

SPORADIC LATE ONSET NEMALINE MYOPATHY WITH MONOCLONAL PROTEIN IS A MALIGNANCY AND SHOULD BE TREATED WITH CHEMOTHERAPY-BASED APPROACH

EHA Library, Rouslan Kotchetkov, 293536

DREAMM-2 PIVOTAL STUDY: ANALYSIS OF THE LYOPHILIZED PRESENTATION COHORT OF SINGLE-AGENT BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, PAUL RICHARDSON, 293537

POST-AUTHORIZATION SAFETY STUDY COMPARING LENALIDOMIDE-BASED TREATMENT VS NON−LENALIDOMIDE-BASED TREATMENT IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Barbara Gamberi, 293538

A REAL-WORLD COMPARATIVE EFFECTIVENESS ANALYSIS OF PROTEASOME INHIBITOR-BASED REGIMENS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA UTILIZING A NATIONWIDE DATABASE IN JAPAN

EHA Library, Hirokazu Tanaka, 293539

THE RELATIONSHIP BETWEEN NEGATIVITY OF SERUM FREE LIGHT CHAINS, MINIMAL RESIDUAL DISEASE, AND OVERALL SURVIVAL IN PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA

EHA Library, Kentaro Narita, 293540

DOUBLE AND TRIPLE HIT MULTIPLE MYELOMA: NEW ULTRA HIGH-RISK ENTITIES?

EHA Library, Aleksandra Sretenovic, 293541

EFFECT OF PROLONGED TREATMENT WITH CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

EHA Library, Cécile Gruchet, 293542

GAIT SPEED AND HANDGRIP TEST TO ASSESS PHYSICAL FRAILTY IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Sotirios Bristogiannis, 293543

AUTOLOGOUS STEM CELL TRANSPLANT AFTER INDUCTION THERAPY IMPROVES OUTCOME IN INITIALLY INELIGIBLE PATIENTS WITH SYSTEMIC IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS

EHA Library, Ilaria Cappuccio, 293544

SURVIVAL TRENDS IN MULTIPLE MYELOMA AFTER AUTOLOGOUS HEMATOPIETIC STEM CELL TRANSPLANTATION

EHA Library, Samer Srour, 293545

CLINICAL PHENOTYPES AND BLOOD FEATURES ASSOCIATED WITH CLONAL MYELOPOIESIS IN THE UK BIOBANK COHORT: ASXL1 MUTATIONS ARE STRONGLY ASSOCIATED WITH SMOKING HISTORY

EHA Library, Nick Cross, 293546

EXPLOITING THE CD47-SIRPΑ MACROPHAGE CHECKPOINT TO CONTROL POLYCYTHEMIA VERA

EHA Library, Veronika Lysenko, 293547

IN SYSTEMIC MASOCYTOSIS, MIDOSTAURIN TARGETS BOTH KIT AND AURORA KINASE A REVERTING H3K36ME3 DEFICIENCY AND SYNERGIZES WITH NILOTINIB AND DASATINIB

EHA Library, Manuela Mancini, 293548

CLONAL HETEROGENEITY AND EVOLUTION OF MPN REVEALED BY SINGLE-CELL RNA/DNA SEQUENCING

EHA Library, Xingxing Qi, 293549

SETD2 PROTEIN LEVELS ARE A NOVEL PREDICTOR OF OVERALL SURVIVAL IN SYSTEMIC MASTOCYTOSIS

EHA Library, Michela Rondoni, 293550

IL-1RA LEVEL IN THE SERUM IS STRONGLY CORRELATED WITH THE JAK2V617F ALLELE BURDEN, MYELOFIBROSIS, SPLENOMEGALY AND SLAMF7HIGH CD16− MONOCYTES IN THE PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Takaaki Maekawa, 293552

HLA CLASS I GENOTYPE SHAPES JAK2 V617F DRIVEN LEUKEMOGENESIS

EHA Library, Velizar Shivarov, 293553

A NOVEL IN VITRO PLATFORM FOR THE PRIORITISATION AND VALIDATION OF INHIBITORS OF BONE MARROW FIBROSIS USING HUMAN BONE MARROW (BM) STROMAL CELLS

EHA Library, Michela Colombo, 293554

NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES TO IDENTIFY POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME

EHA Library, Martina Barone, 293555

NECROPTOTIC SIGNALING IS ENHANCED IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) FROM PATIENTS WITH MYELOFIBROSIS (MF)

EHA Library, Veronika Dill, 293556

HOMOZYGOUS CALRETICULIN MUTATIONS AFFECT CHAPERONE FUNCTION AND PERTURB THE GLYCOPROTEOME

EHA Library, Patrick Schürch, 293557

THE NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IS A CHEAP SURROGATE OF THE IMMUNESUPPRESSIVE MICROENVIRONMENT IN MYELOFIBROSIS AND MAY PREDICT RESPONSE TO RUXOLITINIB

EHA Library, ALESSANDRA ROMANO, 293558

EXPRESSION OF CD47 AND CALR IN MYELOPROLIFERATIVE NEOPLASMS: POTENTIAL NEW THERAPEUTICAL TARGETS

EHA Library, Ciro Rinaldi, 293560

REWIRED CELL ENERGY METABOLISM IN A NOVEL KRAS-MUTATED HISTIOCYTOSIS CHARACTERIZED BY SEVERE SYNOVITIS

EHA Library, Giulio Cavalli, 293561

FREQUENCY OF BCR-ABL1, JAK2V617F, MPLW515L/K AND CALR TYPE 1,2 MUTATIONS CO-OCCURENCE IN CML PATIENTS UNDERGOING TKI THERAPY AND ITS POSSIBLE PROGNOSTIC VALUE

EHA Library, Adhamjon Abdullaev, 293562

MOLECULAR CHARACTERISATION OF THE DER(6)T(1;6) IN MYELOID NEOPLASMS

EHA Library, Sophie Laird, 293563

PHENFORMIN INCREASES THE FREQUENCIES OF LSK, MULTIPOTENT PROGENITOR, AND MYELOID PROGENITOR IN JAK2V617F MURINE MODEL OF MYELOPROLIFERATIVE NEOPLASM

EHA Library, Antonio Bruno Alves-Silva, 293564

CLINICAL AND BIOLOGICAL FEATURES DISTINGUISH MYELOID DISEASES FROM MYELOID DISORDERS ASSOCIATED WITH AUTOIMMUNE DISEASES.

EHA Library, Sara Galimberti, 293565

CLINICAL SIGNIFICANCE OF MPL MUTATIONS IN ESSENTIAL THROMBOCYTEMIA PATIENTS: RISK ASSESMENT OF MYELOFIBROTIC TRANSFORMATION.

EHA Library, Rocío García-Serra, 293566

ROLE OF TRAINED IMMUNITY AND IMMUNOMETABOLISM IN THE PATHOGENESIS OF ERDHEIM-CHESTER DISEASE

EHA Library, Giulio Cavalli, 293567

AVAPRITINIB INDUCES RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM), REGARDLESS OF PRIOR MIDOSTAURIN THERAPY

EHA Library, Jason Gotlib, 293568

A PHASE 2 STUDY OF BOMEDEMSTAT (IMG-7289), A LYSINE-SPECIFIC DEMETHYLASE-! (LSD!) INHIBITOR, FOR THE TREATMENT OF LATER-STAGE MYELOFIBROSIS (MF)

EHA Library, Kristen Pettit, 293569

NAVITOCLAX IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS: A PHASE 2 STUDY

EHA Library, Claire Harrison, 293570

RESULTS FROM PIONEER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF AVAPRITINIB IN PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS

EHA Library, Cem Akin, 293571

CPI-0610, BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS 'ADD-ON' TO RUXOLITINIB (RUX), IN ADVANCED MYELOFIBROSIS PATIENTS WITH SUBOPTIMAL RESPONSE: UPDATE OF MANIFEST PHASE 2 STUDY

EHA Library, Srdan Verstovsek, 293572

CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR TREATMENT NAÏVE MYELOFIBROSIS PATIENTS: UPDATE FROM MANIFEST PHASE 2 STUDY

EHA Library, John Mascarenhas, 293573

ROPEGINTERFERON ALPHA-2B IS EFFICACIOUS AND REDUCES VARIANT TET2 ALLELE BURDEN IN PATIENTS WITH POLYCYTHAEMIA VERA AND TET2 MUTATION: GENETIC ANALYSIS OF PHASE III PROUD-PV/CONTINUATION-PV STUDIES

EHA Library, Robert Kralovics, 293574

CO-MUTATIONS AND NON-CANONICAL DRIVER MUTATIONS IDENTIFIED BY NEXT GENERATION SEQUENCING IN MYELOPROLIFERATIVE NEOPLASMS REVEAL SIGNIFICANT OPPORTUNITIES FOR IMPROVED DIAGNOSTIC PRACTICE

EHA Library, Ella Thompson, 293576

CLINICIAL, MORPHOLOGICAL AND GENETIC EVIDENCE FOR TWO INDEPENDENT DISEASES IN PATIENTS CONCURRENTLY POSITIVE FOR JAK2 V617F AND KIT D816V

EHA Library, Juliana Schwaab, 293577

INTERIM ANALYSIS OF A PHASE II TRIAL (HOVON-134) IN MYELOFIBROSIS PATIENTS (PRIMARY, POST-ET OR POST PV-MF) TREATED WITH THE JAK2 INHIBITOR PACRITINIB BEFORE RIC ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Peter te Boekhorst, 293578

CHRONIC NEUTROPHILIC LEUKEMIA AND ATYPICAL CHRONIC MYELOID LEUKEMIA ARE HIGLY OVERLAPPING DISORDERS. RESULTS FROM AN INTERNATIONAL BRITISH-SPANISH STUDY

EHA Library, Gonzalo Carreno Gomez-Tarragona, 293579

CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS MONOTHERAPY IN ADVANCED MYELOFIBROSIS PATIENTS REFRACTORY/INTOLERANT TO JAK INHIBITOR: UPDATE FROM PHASE 2 MANIFEST STUDY

EHA Library, Moshe Talpaz, 293580

MYELOPROLIFERATIVE NEOPLASMS-UNCLASSIFIABLE: CLINICOPATHOLOGICAL CHARACTERISATION AND OUTCOME ANALYSIS

EHA Library, Paul Deschamps, 293581

PHENOTYPIC DIFFERENCES AND PROGNOSTIC IMPACT OF SIGNALING MUTATIONS IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

EHA Library, Evandro Bezerra, 293582

METFORMIN AND STATINS DO NOT LOWER MYELOFIBROSIS INCIDENS, OVERALL SURVIVAL OR RISK OF LEUKEMIC TRANFORMATION: A DANISH NATIONWIDE COHORT STUDY

EHA Library, Daniel Kristensen, 293583

LONG-TERM SAFETY OF FEDRATINIB IN PATIENTS WITH INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF)

EHA Library, Animesh Pardanani, 293585

SECOND PRIMARY MALIGNANCY IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

EHA Library, Francesca Palandri, 293586

TELOMERASE ACTIVITY, TELOMERE LENGTH AND HTERT EXPRESSION CORRELATE WITH CLINICAL OUTCOMES IN HIGHER-RISK MYELOFIBROSIS (MF) RELAPSED/REFRACTORY (R/R) TO JANUS KINASE INHIBITOR TREATED WITH IMETELSTAT

EHA Library, John Mascarenhas, 293587

MYELOABLATIVE FLUDARABINE AND BUSULFAN REGIMEN IN MYELOFIBROSIS: LONG TERM OUTCOMES AND ANALYSIS OF PROGNOSTIC FACTORS

EHA Library, Jacinth Joseph, 293588

KIDNEY DYSFUNCTION IS ASSOCIATED WITH INCREASED THROMBOSIS BUT NOT SEVERE BLEEDING EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: AN ANALYSIS FROM THE GERMAN GSG-MPN BIOREGISTRY

EHA Library, Steffen Koschmieder, 293589

IMETELSTAT TREATMENT RESULTS IN CLINICAL BENEFITS, INCLUDING IMPROVED OVERALL SURVIVAL, IN PATIENTS WITH HIGHER-RISK TRIPLE-NEGATIVE MYELOFIBROSIS RELAPSED/REFRACTORY TO JANUS KINASE INHIBITORS (JAKI)

EHA Library, Jean-Jacques Kiladjian, 293590

THE WHO SUBCATEGORY 'MYELOID/LYMPHOID NEOPLASMS WITH EOSINOPHILIA AND REARRANGEMENT OF PDGFRA, PDGFRB OR FGFR1, OR PCM1-JAK2' REVISITED IN 74 PATIENTS: LACK OF EOSINOPHILIA AND PRESENCE OF MONOCYTOSIS

EHA Library, Laurenz Steiner, 293591

MOMELOTINIB DOSE-INTENSITY IS MAINTAINED IN JAK INHIBITOR NAÏVE AND PREVIOUSLY JAK INHIBITOR TREATED INTERMEDIATE/HIGH RISK MYELOFIBROSIS PATIENTS

EHA Library, Vikas Gupta, 293592

USE OF NEXT GENERATION SEQUENCING GENE PANEL FOR IDIOPATHIC ERYTHROCYTOSIS IN A SINGLE CENTRE

EHA Library, Rebekah Williams, 293593

MYSEC-PROGNOSTIC MODEL AND PREVIOUS THROMBOTIC EVENTS PREDICT THE RISK OF THROMBOSIS IN POST POLYCYTHEMIA VERA AND POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A STUDY OF THE MYSEC GROUP

EHA Library, Barbara Mora, 293594

HAEMATOLOGICAL MALIGNANCIES IN RELATIVES OF PATIENTS AFFECTED WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Daniele Vanni, 293595

FAVORABLE OVERALL SURVIVAL WITH IMETELSTAT TREATMENT CORRELATES WITH OTHER CLINICAL BENEFITS IN INTERMEDIATE 2 OR HIGH RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JANUS KINASE INHIBITOR

EHA Library, John Mascarenhas, 293596

MUTATIONAL GENOMIC PROFILE OF TRIPLE-NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS USING NEXT-GENERATION SEQUENCING

EHA Library, Sara Duarte, 293597

EARLY ONSET OF SPLEEN AND SYMPTOM RESPONSES WITH FEDRATINIB (FEDR) IN PATIENTS WITH INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF)

EHA Library, Francesco Passamonti, 293598

PULMONARY HYPERTENSION IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASM: A SINGLE CENTER RETROSPECTIVE ANALYSIS OF 225 PATIENTS

EHA Library, Ik-Chan Song, 293599

OUTCOMES OF 99 PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN) ASSOCIATED SPLANCHNIC VEIN THROMBOSIS (SVT): FIRST REPORT FROM THE UK MASCOT REGISTRY

EHA Library, Hannah Brown, 293600

PATIENT-REPORTED PHYSICAL, EMOTIONAL AND ECONOMIC IMPACT OF MYELOPROLIFERATIVE NEOPLASMS IN AN EXPANSION OF THE MPN LANDMARK SURVEY

EHA Library, Guray Saydam, 293601

LONG TERM SAFETY OF MOMELOTINIB IN JAK INHIBITOR NAÏVE AND PREVIOUSLY JAK INHIBITOR TREATED INTERMEDIATE/HIGH RISK MYELOFIBROSIS PATIENTS

EHA Library, Claire Harrison, 293602

A POPULATION-BASED STUDY OF CHRONIC EOSINOPHILIC LEUKEMIA-NOT OTHERWISE SPECIFIED IN THE UNITED STATES: 2004-2015

EHA Library, Gordon Ruan, 293603

RUXOLITINIB IN PV PATIENTS RESISTANT AND/OR INTOLERANT TO HYDROXYUREA: INTERIM ANALYSIS OF A EUROPEAN MULTI-CENTRIC OBSERVATIONAL STUDY

EHA Library, Peter te Boekhorst, 293604

RUXOLITINIB COMBINED WITH PREDNISONE, THALIDOMIDE AND DANAZOL THERAPY IN MYELOFIBROSIS: A RETROSPECTIVE COHORT STUDY

EHA Library, Zhijian Xiao, 293605

MACHINE-LEARNING TO PREDICT HYDROXYUREA (HU) FAILURE AND INCIDENCE OF THROMBOEMBOLIC EVENTS (TES) WITH HU VS RUXOLITINIB SWITCH THERAPY IN POLYCYTHEMIA VERA PATIENTS

EHA Library, Srdan Verstovsek, 293606

CLINICAL-PATHOLOGICAL FEATURES OF TRIPLE-NEGATIVE ESSENTIAL THROMBOCHYTEMIA

EHA Library, Daniele Cattaneo, 293607

USE OF BIOSIMILAR ERYTHROPOIESIS STIMULANTING AGENTS FOR ANEMIA IN MYELOFIBROSIS: A MULTICENTER REAL-LIFE EXPERIENCE ON 40 PATIENTS

EHA Library, Elena Inzoli, 293608

REAL-WORLD SURVIVAL IN ELDERLY PATIENTS WITH MYELOFIBROSIS IN THE UNITED STATES: PRE- VS POST-RUXOLITINIB APPROVAL

EHA Library, Srdan Verstovsek, 293609

PREGNANCY OUTCOMES IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS – PALG (POLISH ADULT LEUKEMIA GROUP) A RECENT, EXTENDED RETROSPECTIVE ANALYSIS

EHA Library, Bozena Sokolowska, 293610

USE OF NEXT-GENERATION SEQUENCING TO IDENTIFY MYELOID MUTATIONS ASSOCIATED WITH THROMBOTIC RISK IN PATIENTS WITH POLYCYTHEMIA VERA

EHA Library, Ruth Stuckey, 293611

TREATMENT AND DISEASE MANAGEMENT PRACTICES IN PATIENTS WITH MPNS IN 6 COUNTRIES: AN EXPANSION OF THE MPN LANDMARK SURVEY

EHA Library, Cheng-Shyong Chang, 293612

REAL-WORLD SURVIVAL IN ELDERLY PATIENTS WITH MYELOFIBROSIS IN THE UNITED STATES: RUXOLITINIB EXPOSED VS UNEXPOSED

EHA Library, Srdan Verstovsek, 293613

IMPACT OF PLATELET COUNT ON THROMBOTIC RISK IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA WITH NORMAL LEUKOCYTE COUNT

EHA Library, Veronika Buxhofer-Ausch, 293614

RUXOLITINIB IN MYELOFIBROSIS: A MULTICENTRE ANALYSIS OF REAL-WORLD PATIENTS IN ENGLAND, NORTHERN IRELAND AND WALES

EHA Library, James Russell, 293615

SPLEEN STIFFNESS MEASUREMENT BY USING SHEAR-WAVE ELASTOGRAPHY AS A PREDICTOR OF PROGRESSION TO SECONDARY MYELOFIBROSIS

EHA Library, Omer Ekinci, 293616

SECOND CANCER IN MYELOFIBROSIS TREATED WITH RUXOLITINIB: A 'REAL-LIFE' RETROSPECTIVE MULTICENTER EXSPERIENCE OF THE RETE EMATOLOGICA PUGLIESE (REP)

EHA Library, Erminia Rinaldi, 293617

IMPACT OF INTERIM PET ON HODGKIN LYMPHOMA TREATMENT OUTCOMES AND SURVIVAL IN CLINICAL PRACTICE.

EHA Library, Serena Zheng, 293618

DOSE-INTENSIFICATION IN EARLY UNFAVORABLE HODGKIN LYMPHOMA: LONG-TERM FOLLOW UP OF THE GERMAN HODGKIN STUDY GROUP (GHSG) HD14 TRIAL

EHA Library, Bastian Von Tresckow, 293619

NIVOLUMAB IN COMBINATION WITH CHEMOTHERAPY OR TARGETED THERAPY IN THE TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY CLASSICAL HODGKIN LYMPHOMA

EHA Library, Liudmila Fedorova, 293620